8-K 1 a06-3922_28k.htm CURRENT REPORT OF MATERIAL EVENTS OR CORPORATE CHANGES

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)  February 1, 2006

 

Medicsight, Inc

(Exact name of registrant as specified in its charter)

 

Delaware

 

0-26886

 

13-4148725

(State or other jurisdiction
of incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

 

 

 

 

46 Berkeley Square, London, United Kingdom

 

W1J 5AT

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code     011-44-20-7598-4070

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

ITEM 8.01.                                    Other Events

 

On February 1, 2006 Medicsight PLC, Medicsight, Inc’s majority owned subsidiary, and Viatronix Inc., a Stony Brook, New York-based industry leader in 2D/3D clinical solutions, announced today that Medicsight ColonCAD, integrated as part of the Viatronix V3D-Colon workstation, will be used in the SIGGAR1 clinical trial to interpret CT colonography (virtual colonoscopy) studies.

 

ITEM 9.01.            Financial Statements and Exhibits

 

The press release, dated February 1, 2006, announcing information on the SIGGAR1clinical trial is filed as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

MEDICSIGHT, INC.

 

By:

/s/ Paul Gothard

 

 

Paul Gothard

 

Chief Financial Officer

Date:  February 1, 2006

 

 

2


 

Exhibit Index

 

Exhibit No.

 

Description

 

 

 

EX 99.1

 

Press release dated February 1, 2006 announcing information on the SIGGAR1 clinical trial.

 

3